Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research

Autor:	Polhemus, Mark E., Magill, Alan J., Cummings, James F., Kester, Kent E., Ockenhouse, Chris F., Lanar, David E., Dutta, Sheetij, Barbosa, Arnoldo, Soisson, Lorraine, Diggs, Carter L., Robinson, Sally A., Haynes, John D., Stewart, V. Ann, Ware, Lisa A., Brando, Clara, Krzych, Urszula, Bowden, Robert A., Cohen, Joe D., Dubois, Marie-Claude, Ofori-Anyinam, Opokua, De-Kock, Els, Ballou, W. Ripley, Heppner, D. Gray, Jr.
Zdroj:	In Vaccine 22 May 2007 25(21):4203-4212
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect